Get the Stockscreener App
27.58
0.40%
0.11
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.58, with a volume of 36.93M.
It is up +0.40% in the last 24 hours and up +9.66% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.47
Open:
$27.6
24h Volume:
36.93M
Relative Volume:
0.66
Market Cap:
$156.81B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
20.35
EPS:
1.3551
Net Cash Flow:
$10.38B
1W Performance:
+1.32%
1M Performance:
+9.66%
6M Performance:
+9.62%
1Y Performance:
+7.57%
1-Day Range:
$27.55
$27.94
1-Week Range:
$26.79
$27.94
52-Week Range:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.58 | 156.19B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Stock (PFE) Opinions on Market Rotation to Defensives - Quiver Quantitative
Pfizer Inc. $PFE Shares Bought by State of New Jersey Common Pension Fund D - MarketBeat
TCTC Holdings LLC Reduces Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Bought by Aberdeen Group plc - MarketBeat
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? - The Motley Fool
Public Sector Pension Investment Board Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Assetmark Inc. Buys 193,859 Shares of Pfizer Inc. $PFE - MarketBeat
Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings - Finviz
Pfizer Advances VESPER-5 Obesity and Diabetes Trial, Targeting a Key Growth Market - TipRanks
Fund Update: 753,189 PFIZER (PFE) shares added to THORNBURG INVESTMENT MANAGEMENT INC portfolio - Quiver Quantitative
Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds? - Insider Monkey
Pfizer Hemophilia And Obesity Updates Add Context To Valuation Debate - simplywall.st
Versor Investments LP Sells 37,800 Shares of Pfizer Inc. $PFE - MarketBeat
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - Yahoo Finance
Pfizer (NYSE:PFE) Lowered to "Hold" Rating by Daiwa America - MarketBeat
Pfizer Inc. $PFE Shares Sold by Prospera Financial Services Inc - MarketBeat
Pfizer Inc. $PFE Position Cut by CENTRAL TRUST Co - MarketBeat
Pfizer Inc. $PFE Stake Reduced by GFS Advisors LLC - MarketBeat
Illinois Municipal Retirement Fund Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Sees Mixed Options Sentiment Amid Stock Downgrade - GuruFocus
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - Barchart.com
Varma Mutual Pension Insurance Co Purchases 82,500 Shares of Pfizer Inc. $PFE - MarketBeat
ING Groep NV Lowers Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by LSV Asset Management - MarketBeat
Pfizer (NYSE:PFE) Cut to Neutral at Daiwa Securities Group - MarketBeat
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More - 24/7 Wall St.
Madison Asset Management LLC Has $6.17 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Shares Hit Annual Peak on Regulatory and Strategic Momentum - AD HOC NEWS
Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… - marketscreener.com
Caprock Group LLC Makes New Investment in Pfizer Inc. $PFE - MarketBeat
Daiwa Securities Downgrades Pfizer to Neutral From Outperform, Price Target is $27 - marketscreener.com
Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook - Yahoo! Finance Canada
Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute - Law360
Pfizer: A Great Opportunity Post Earnings (NYSE:PFE) - Seeking Alpha
Pfizer, SEC Reach $29M End to Scrap Over Insider Trading Settlement - Law.com
Pfizer Balances New Therapies And Pricing With Fresh Biotech Partnerships - simplywall.st
Is Now the Best Time to Buy Pfizer Stock? - The Globe and Mail
Pfizer Reports Strong Earnings OutlookUnusual Call Options Activity Shows Investors are Bullish - Barchart.com
Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders - Finviz
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? - The Globe and Mail
Is Pfizer Stock Now A Value Trap? - Forbes
Wealthfront Advisers LLC Has $14.76 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Oppenheimer Asset Management Inc. - MarketBeat
Enzyme Inhibitors Market Is Going to Boom |• Pfizer • Merck & Co. - openPR.com
Is Pfizer Stock Heading for a Fall? - Trefis
Pfizer Inc. $PFE Shares Bought by Advisors Asset Management Inc. - MarketBeat
Can Pfizer Stock Withstand These Pressures? - Trefis
Pfizer Gets $29 Million of SAC Capital Insider Trade SEC Payout - Bloomberg Law News
Pfizer (NYSE:PFE) Shares Up 2.1%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Sets New 1-Year HighStill a Buy? - MarketBeat
Pfizer stock hits 52-week high at 27.7 USD - Investing.com
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):